| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Galectin Therapeutics Inc (GALT) has 14 insiders with recent SEC Form 4 filings, including 1 buy and 23 sells. GALT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 10.33M | $21.70M | - | |
| 10% | 5.61M | $11.79M | - | |
| CFO | 100.0K | $210.0K | - | |
| CEO | 100.0K | $210.0K | - | |
| Other | 100.0K | $210.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2018 | Omenn Gilbert S | Director | Sell | 19,370 | $6.02 | $116,585.20 | -15.6% | |
| Sep 4, 2018 | Rubin Marc | Director | Sale+OE | 11,900 | $6.58 | $78,255.59 | -36.6% | |
| Aug 30, 2018 | Rubin Marc | Director | Sale+OE | 58,100 | $6.08 | $353,311.91 | -68.7% | |
| Jun 25, 2018 | Lewis Joel | Director | Buy | 1,000 | $7.06 | $7,058.40 | +2.0% | |
| Jun 20, 2018 | Callicutt Jack W62 | Chief Financial Officer | Sale+OE | 226,000 | $8.61 | $1,946,021.40 | -98.9% | |
| Jun 18, 2018 | Czirr James C | - | Sell | 151,860 | $8.61 | $1,306,806.65 | -1.4% | |
| Jun 18, 2018 | 10x Fund, L.P.85 | - | Sell | 151,860 | $8.61 | $1,306,806.65 | -1.4% | |
| Jun 13, 2018 | Czirr James C | - | Sell | 208,140 | $7.17 | $1,493,275.80 | -1.8% | |
| Jun 13, 2018 | Traber Peter G59 | President &CEO | Sale+OE | 100,000 | $7.51 | $751,000.00 | -48.2% | |
| Jun 13, 2018 | 10x Fund, L.P.85 | - | Sell | 208,140 | $7.17 | $1,493,275.80 | -1.8% |